Vanrafia in United Arab Emirates
How patients in United Arab Emirates access Vanrafia (atrasentan) via Named Patient Program.
Vanrafia - overview
Vanrafia (atrasentan) is manufactured by TBD – verify (vosoritide/vafidemstat?) and indicated for Rare/Neuro/Endocrine program – confirm exact product. It is a ETA antagonist approved by the US FDA in 2025 and may be accessible to patients in United Arab Emirates through a Named Patient Program or personal-import pathway.
Access in United Arab Emirates
The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
How Reserve Meds coordinates access in United Arab Emirates
- Patient or treating physician submits a request.
- We verify clinical appropriateness and United Arab Emirates-specific eligibility.
- Treating physician in United Arab Emirates issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Vanrafia from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in United Arab Emirates.
Typical timeline for United Arab Emirates
End-to-end, most requests are completed in 2-6 weeks. United Arab Emirates's tier 1 regulatory maturity typically supports fast processing times.
What patients and physicians in United Arab Emirates ask
- Is the pathway legal in United Arab Emirates? Yes - it operates under United Arab Emirates's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in United Arab Emirates able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.